Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:333-344
Published online before print January 8, 2007, doi: 10.1161/CIRCULATIONAHA.106.643296
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
115/3/333    most recent
CIRCULATIONAHA.106.643296v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walther, T.
Right arrow Articles by Dörner, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walther, T.
Right arrow Articles by Dörner, A.
Related Collections
Right arrow Cardio-renal physiology/pathophysiology
Right arrow Structure
Right arrow Biochemistry and metabolism
Right arrow Animal models of human disease
Right arrow Apoptosis
Right arrow Hypertrophy

(Circulation. 2007;115:333-344.)
© 2007 American Heart Association, Inc.


Hypertension

Accelerated Mitochondrial Adenosine Diphosphate/Adenosine Triphosphate Transport Improves Hypertension-Induced Heart Disease

Thomas Walther, PhD*; Carsten Tschöpe, MD*; Anja Sterner-Kock, PhD, DVM; Dirk Westermann, MD; Silvia Heringer-Walther, MD, PhD; Alexander Riad, MD; Alen Nikolic, MD; Yong Wang, MSc; Linda Ebermann, MSc; Wolf-Eberhard Siems, PhD; Michael Bader, PhD; Mehdi Shakibaei, PhD; Heinz-Peter Schultheiss, MD; Andrea Dörner, PhD

From the Department of Cardiology, Charité-Universitätsmedizin Berlin, Berlin, Germany (T.W., C.T., D.W., S.H.-W., A.R., A.N., L.E., H.-P.S., A.D.); Department of Pharmacology, Erasmus Medical Center, Rotterdam, the Netherlands (T.W., S.H.-W., Y.W.); Institute for Veterinary Pathology, Freie Universität, Berlin, Germany (A.S.-K.); Leibniz Institut für Molekulare Pharmakologie, Berlin-Buch, Germany (W.-E.S.); Max-Delbrück Center for Molecular Medicine, Berlin-Buch, Germany (M.B.); and Institute of Anatomy, Ludwig-Maximillians University, Munich, Germany.

Correspondence to Thomas Walther, Charité-Universitätsmedizin, Campus Benjamin Franklin, Department of Cardiology and Pneumonology, Hindenburgdamm 30, 12200 Berlin, Germany. E-mail thomas.walther{at}charite.de

Received June 1, 2006; accepted November 7, 2006.

Background— Strong evidence suggests that mitochondrial malfunction, which leads to disturbed energy metabolism and stimulated apoptosis, is a linchpin in the induction and manifestation of cardiac failure. An adequate exchange of ATP and ADP over the inner mitochondrial membrane by the adenine nucleotide translocase (ANT) is thereby essential to guarantee the cellular energy supply.

Methods and Results— To explore the effect of an ameliorated mitochondrial ATP/ADP transportation on cardiac dysfunction, we generated transgenic rats overexpressing ANT1 in the heart (ANT rats) and crossed them with renin-overexpressing rats (REN rats) suffering from hypertension-induced cardiac insufficiency. Cardiac-specific ANT1 overexpression resulted in a higher ATP/ADP transportation and elevated activities of respiratory chain complexes. Increased ANT activity in double-transgenic (ANT/REN) animals did not influence excessive hypertension seen in REN rats. Hypertension-induced cardiac hypertrophy in the REN rats was prevented by parallel ANT1 overexpression, however, and left ventricular function remarkably improved. The ANT1 overexpression led to a reduction in fibrosis and an improvement in cardiac tissue architecture. Consequently, the survival rate of ANT/REN rats was enhanced. Further investigations into the cardioprotective mechanism of ANT1 overexpression revealed improved mitochondrial structure and function and significantly reduced apoptosis in ANT/REN rats, shown by lowered cytosolic/mitochondrial cytochrome c ratio, reduced caspase 3 level, and prevented DNA degradation.

Conclusions— Myocardial ANT1 overexpression protects against hypertension-induced cardiac pathology. Thus, the improvement in mitochondrial function may be a basic principle for new strategies in treating heart disease.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
FASEB J.Home page
F. Gembardt, S. Heringer-Walther, J. H.M. van Esch, A. Sterner-Kock, R. van Veghel, T. H. Le, I. M. Garrelds, T. M. Coffman, A.H. J. Danser, H.-P. Schultheiss, et al.
Cardiovascular phenotype of mice lacking all three subtypes of angiotensin II receptors
FASEB J, August 1, 2008; 22(8): 3068 - 3077.
[Abstract] [Full Text] [PDF]